A FORMULATION INTENDED FOR TREATMENT OF RENAL FAILURE
Creators: name: Alkoclar, Erdal Can
Publisher: name: Zenodo
Year: 2020
Subjects: ACTH CRF CAMP

description: The present invention herewith is related to a formulation developed for treatment of renal failure. <strong>Background of the Related Technology</strong> At present renal failure is known to develop when the kidneys cannot function properly. The most prominent indication of renal failure is the increase of certain hazardous components in the blood like urea and creatinine. Renal failure can develop in two ways: It may develop suddenly (acute renal failure): It develops very fast within days or even hours. The damage in the kidney is generally reversible (recovered) with time. Dialysis may be required only at times the kidneys are not functioning. It may develop quietly and slowly within years (chronic renal failure): This is a progressive disease that damages the kidneys slowly with time. It may take many years and no indication may be observed until the disease progresses considerably. In both cases, since the kidneys cannot excrete the substances hazardous for the body, such substances accumulate in the blood affecting various tissues, organs and systems. The invention presented herewith with no "EP1132086B1", with title "Using Prostaglandin (pge2) Receptor 4 (ep4) Selective Agonists in Treatment of Acute and Chronic Renal Failure” and under classification number "A61K 31/4015", is related to treatment of acute and chronic renal failure or dysfunction or conditions caused by such a failure and is related to the methods and compositions that include application of prostaglandin agonists, which are EP4 receptor selective prostaglandin agonists. Again the invention presented herewith with no "EP1581227B1", with title "A Method for Treatment of Renal Failure” and under classification number "A61K 31/50", is related to levosimendan or an active metabolite (II), which were proposed earlier for congestive cardiac failure and is useful in renal treatment. Again the invention presented herewith with no "EP1948216B1", with title "Treatment of Acute Renal Failure with Soluble Thrombomoduline” and under classification number "A61K 38/17", is related to a method for preventing acute kidney failure that is caused by various health problems and/or for treatment of people suffering from such a failure. This method includes administrating dissolved thrombomoduline to the patient. Together with standard patient care, administration of soluble thrombomoduline will reduce damage to the tissues and later reduce the rate of morbidity and mortality. To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation intended for treatment of renal failure. <strong>Objective of the Invention</strong> To overcome the disadvantages referred in the Background of the Related Technology, One objective of the present invention is, to trigger the general positive improvement in renal function via active cAMP increase; One other objective of the invention is to trigger production of acth; One other objective of the invention is to triggers production of crf; One other objective of the invention is to enhance natural dhea production by direct zona reticularis stimulation capability; One other objective of the invention is to ensure stimulation of steroidogenesis. The present invention which is aimed to achieve the above-mentioned advantages, is intended for treatment of renal failure and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 2,6-octadienyl]-2,4-trimethoxycafeoyl]-6-(7-dihydroxyphenyl)-3-propene-4-one, 3,7-bis((3-methyl-2-butene-1-yl)-4H-1-benzopyran-4-one, trimethyl-2,4-trimethoxycafeoyl]-6-(7-dihydroxyphenyl)-3-propene-4-one, 7-alpha-(3β,25R)-spirost-6-ene-3-one, 7-oxo-(3β,7B,25R)-spirost-5-ene-3-triol. Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith. <strong>Detailed Description of the Invention</strong> The present invention is related to a formulation developed for treatment of renal failure. The referred formulation triggers the general positive improvement in renal function via active cAMP increase, triggers production of acth, triggers production of crf, enhances natural dhea production by direct zona reticularis stimulation capability, ensures stimulation of steroidogenesis. The formulation related to the present invention herewith contains; 2,6-octadienyl]-2,4-trimethoxycafeoyl]-6-(7-dihydroxyphenyl)-3-propene-4-one, 3,7-bis((3-methyl-2-butene-1-yl)-4H-1-benzopyran-4-one, trimethyl-2,4-trimethoxycafeoyl]-6-(7-dihydroxyphenyl)-3-propene-4-one, 7-alpha-(3β,25R)-spirost-6-ene-3-one, 7-oxo-(3β,7B,25R)-spirost-5-ene-3-triol . The referred formulation is formed by mixing the above-mentioned components at below percentages by weight; 12-17% of 2,6-octadienyl]-2,4-trimethoxycafeoyl]-6-(7-dihydroxyphenyl)-3-propene-4-one, 13-23% of trimethyl-2,4-trimethoxycafeoyl]-6-(7-dihydroxyphenyl)-3-propene-4-one, 30-25% of 3,7-bis((3-methyl-2-butene-1-yl)-4H-1-benzopyran-4-one, 3-7% of 7-alpha-(3β,25R)-spirost-6-ene-3-one, 42-28% of 7-oxo-(3β,7B,25R)-spirost-5-ene-3-triol. Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof. The present invention at the same time is related to using the above-referred formulation for treatment of renal failure and manufacturing it for such purpose <strong>CLAIMS</strong> A formulation intended for treatment of renal failure, which consists of combining the components selected from the group; 2,6-octadienyl]-2,4-trimethoxycafeoyl]-6-(7-dihydroxyphenyl)-3-propene-4-one, 3,7-bis((3-methyl-2-butene-1-yl)-4H-1-benzopyran-4-one, trimethyl-2,4-trimethoxycafeoyl]-6-(7-dihydroxyphenyl)-3-propene-4-one, 7-alpha-(3β,25R)-spirost-6-ene-3-one, 7-oxo-(3β,7B,25R)-spirost-5-ene-3-triol in a single form or in combinations thereof. The formulation of Claim 1 which is characterized by containing 12-17% of 2,6-octadienyl]-2,4-trimethoxycafeoyl]-6-(7-dihydroxyphenyl)-3-propene-4-one by weight. The formulation of Claim 1 which is characterized by containing 13-23% of trimethyl-2,4-trimethoxycafeoyl]-6-(7-dihydroxyphenyl)-3-propene-4-one by weight. The formulation of Claim 1 which is characterized by containing 30-25% of 3,7-bis((3-methyl-2-butene-1-yl)-4H-1-benzopyran-4-one by weight. The formulation of Claim 1 which is characterized by containing 3-7% of 7-alpha-(3β,25R)-spirost-6-ene-3-one by weight. The formulation of Claim 1 which is characterized by containing 42-28% of 7-oxo-(3β,7B,25R)-spirost-5-ene-3-triol by weight. Using the compositions obtained by selecting singly or in combination of components from the group of; 2,6-octadienyl]-2,4-trimethoxycafeoyl]-6-(7-dihydroxyphenyl)-3-propene-4-one, 3,7-bis((3-methyl-2-butene-1-yl)-4H-1-benzopyran-4-one, trimethyl-2,4-trimethoxycafeoyl]-6-(7-dihydroxyphenyl)-3-propene-4-one, 7-alpha-(3β,25R)-spirost-6-ene-3-one, 7-oxo-(3β,7B,25R)-spirost-5-ene-3-triol from any one as given in Claims 2-6 in manufacturing the formulation intended for treatment of renal failure. <strong>SUMMARY</strong> <strong>A FORMULATION INTENDED FOR TREATMENT OF RENAL FAILURE</strong> The present invention is related to a formulation developed for treatment of renal failure. The referred formulation triggers the general positive improvement in renal function via active cAMP increase, triggers production of acth, triggers production of crf, enhances natural dhea production by direct zona reticularis stimulation capability, ensures stimulation of steroidogenesis.